Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROCIN versus R P MYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROCIN versus R P MYCIN.
ERYTHROCIN vs R-P MYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also exhibits anti-inflammatory and prokinetic effects via motilin receptor agonism.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6 hours.
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in adults; may prolong to 4-6 hours in hepatic impairment or neonates.
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
Primarily eliminated via biliary excretion as unchanged drug and metabolites; approximately 2-5% excreted renally as active drug, 15-20% as metabolites; up to 30% excreted in feces.
Renal (60-80% unchanged), biliary/fecal (15-20%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic